Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update
Gaps in Knowledge (2 of 3)
Evidence is sparse regarding the effectiveness of therapies to prevent or treat osteoporosis in men.
Studies have not directly compared the antifracture effects of longer durations of therapy among the various medications. It is thus unclear how long patients should remain on therapy.
Data are insufficient to determine the comparative effectiveness among individual bisphosphonates or between bisphosphonates and calcium, raloxifene, or teriparatide.
Keywords: bone | low bone density | bone density | osteoporosis | fracture | osteopenia | skeletal | men antifracture | duration | bisphosphonate | calcium | raloxifene | teriparatide
- Newberry SJ, Crandall CC, Gellad WG, et al. Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update to the 2007 Report. Comparative Effectiveness Review No. 53 (Prepared by the Southern California Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ Publication No. 12-EHC023-EF. Available at www.effectivehealthcare.ahrq.gov/reports/lbd.cfm.
Your slide tray is being processed.